Johnson & Johnson’s (J&J) Janssen Vaccines & Prevention has submitted its investigational preventive Ebola prime-boost vaccine regimen for review to the World Health Organisation (WHO) for Emergency Use Assessment and Listing (EUAL).

The EUAL procedure can be implemented at the time of an outbreak of a disease with high rates of morbidity or mortality and when there are no treatment or prevention options.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Johnson & Johnson chief scientific officer Paul Stoffels said: “Over the past four decades, we have seen 25 Ebola outbreaks, with the most recent in West Africa killing seven times more people than all previous outbreaks combined.

“If the WHO grants an emergency use listing, this will accelerate the availability of Janssen’s investigational vaccine regimen to the international community in the event another Ebola crisis occurs.”

"40 years after Ebola’s discovery, the potential availability of a durable prime-boost vaccine would be a tremendous achievement in global health."

UN Member States and procurement agencies will get support from the EUAL to determine the acceptability for use of a specific vaccine in a public health emergency.

See Also:

Prior to granting the investigational preventative vaccine regimen, WHO will evaluate available data including quality, safety, and immunogenicity, as well as a risk / benefit analysis.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Janssen Pharmaceutical Companies infectious diseases and vaccines global therapeutic area head Johan Van Hoof said: “40 years after Ebola’s discovery, the potential availability of a durable prime-boost vaccine would be a tremendous achievement in global health.

“If listed for emergency use, the investigational Janssen vaccine regimen could be a vital prevention tool for rapid outbreak response, particularly for health workers and vulnerable communities on the frontlines.”

Prime-boost vaccination involves giving an initial dose to prime the immune system, followed by a booster dose later on to strengthen and optimise the duration of immunity.